NASDAQ:RVMD Revolution Medicines Q2 2026 Earnings Report $187.53 0.00 (0.00%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$187.00 -0.53 (-0.28%) As of 07/31/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Revolution Medicines EPS ResultsActual EPSN/AConsensus EPS -$2.04Beat/MissN/AOne Year Ago EPSN/ARevolution Medicines Revenue ResultsActual RevenueN/AExpected Revenue$1.77 millionBeat/MissN/AYoY Revenue GrowthN/ARevolution Medicines Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Revolution Medicines Earnings HeadlinesRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 31 at 2:15 AM | americanbankingnews.comRevolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026July 29, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 3 at 1:00 AM | InvestorPlace (Ad)Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?July 25, 2026 | finance.yahoo.comRevolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic CancerJuly 25, 2026 | finance.yahoo.comRevolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerJuly 22, 2026 | markets.businessinsider.comSee More Revolution Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email. Email Address About Revolution MedicinesRevolution Medicines (NASDAQ:RVMD) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance. The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations. These candidates are being evaluated in various phases of clinical development across solid tumors, with the goal of delivering first-in-class or best-in-class therapies for patients with limited treatment options. Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines operates research facilities in North America and collaborates with academic institutions and industry partners to accelerate innovation. The management team comprises experienced executives with deep expertise in oncology drug discovery, guiding the company’s strategic partnerships and clinical advancement efforts.View Revolution Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Strategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance Problem Upcoming Earnings Spotify Technology (8/4/2026)SpaceX (8/4/2026)Electronic Arts (8/4/2026)McDonald's (8/4/2026)Toyota Motor (8/4/2026)Coca-Cola Europacific Partners (8/4/2026)BP (8/4/2026)EOG Resources (8/4/2026)Energy Transfer (8/4/2026)Marathon Petroleum (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
